RO7268489
DrugRO7268489 will be administered per schedule as specified in the arms.
NCT Number: NCT07282574
The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.
Interested in participating?
Request Info18 year–60 year
All sexes
Interventional
Phase 2
Southern Neurology, Kogarah, New South Wales, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
RO7268489 will be administered per schedule as specified in the arms.
Ocrelizumab will be administered per schedule as specified in the arms.
Other names: RO4964913, Ocrevus
Placebo will be administered per schedule as specified in the arms.
Time frame: Up to approximately 110 weeks
Time from randomization to the first occurrence of cCDP12 according to at least one of the following 3 criteria:
Time frame: Up to approximately 110 weeks
The SDMT is a performance measure of processing speed that is widely used to assess cognitive function in response to treatment. It's brief, easy to administer, and involves a simple substitution task that healthy children and adults can easily perform. Using a reference key, the participant has 90 seconds to pair specific numbers with given geometric figures. The total SDMT score is the total number of correct responses and ranges from 0 to 110, with a higher score indicating a higher level of processing speed. A four-point change from baseline is typically considered clinically meaningful.
Time frame: Up to approximately 110 weeks
Time frame: Up to approximately 110 weeks
Time frame: Up to approximately 110 weeks
Time frame: Up to approximately 110 weeks
Time frame: Up to approximately 110 weeks
The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. Lower the mean change in the score over time, the better performance.
Time frame: Up to approximately 110 weeks
The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. Lower the mean change in the score over time, the better performance.
Time frame: Up to approximately 110 weeks
Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time = higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.
Time frame: Up to approximately 110 weeks
Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time = higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.
Time frame: Up to approximately 110 weeks
Time frame: Up to approximately 110 weeks
Time frame: Up to 5 years
Time frame: Up to 5 years
Time frame: Up to 5 years
C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior.
Time frame: Up to 5 years
Contact information is provided by the study sponsor or research team.
Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT
Reference Study ID Number: BP46016 https://forpatients.roche.com/
CONTACT
888-662-6728 (U.S. Only)
Hoffmann-La Roche
Industry
A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis
Acronym: Mintaka
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06675864
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Darlinghurst, New South Wales, Australia
View Trial DetailsNCT07139743
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Redwood City, California, United States
View Trial DetailsNCT07392879
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Ann Arbor, Michigan, United States
View Trial DetailsNCT05811013
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Pozzilli, Isernia, Italy
View Trial Details